AU2016226157B2 - Combination of a PD-1 antagonist and eribulin for treating cancer - Google Patents

Combination of a PD-1 antagonist and eribulin for treating cancer Download PDF

Info

Publication number
AU2016226157B2
AU2016226157B2 AU2016226157A AU2016226157A AU2016226157B2 AU 2016226157 B2 AU2016226157 B2 AU 2016226157B2 AU 2016226157 A AU2016226157 A AU 2016226157A AU 2016226157 A AU2016226157 A AU 2016226157A AU 2016226157 B2 AU2016226157 B2 AU 2016226157B2
Authority
AU
Australia
Prior art keywords
ser
leu
val
thr
eribulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016226157A
Other languages
English (en)
Other versions
AU2016226157A1 (en
Inventor
Gursel AKTAN
Erhan BERRAK
Yasuhiro Funahashi
Vassiliki KARANTZA
Junji Matsui
RuiRong YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Eisai R&D Management Co Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55586425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016226157(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Eisai R&D Management Co Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2016226157A1 publication Critical patent/AU2016226157A1/en
Application granted granted Critical
Publication of AU2016226157B2 publication Critical patent/AU2016226157B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016226157A 2015-03-04 2016-03-03 Combination of a PD-1 antagonist and eribulin for treating cancer Ceased AU2016226157B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128373P 2015-03-04 2015-03-04
US62/128,373 2015-03-04
US201562264068P 2015-12-07 2015-12-07
US62/264,068 2015-12-07
PCT/US2016/020734 WO2016141209A1 (en) 2015-03-04 2016-03-03 Combination of a pd-1 antagonist and eribulin for treating cancer

Publications (2)

Publication Number Publication Date
AU2016226157A1 AU2016226157A1 (en) 2017-09-14
AU2016226157B2 true AU2016226157B2 (en) 2022-01-27

Family

ID=55586425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016226157A Ceased AU2016226157B2 (en) 2015-03-04 2016-03-03 Combination of a PD-1 antagonist and eribulin for treating cancer

Country Status (13)

Country Link
US (1) US10945990B2 (enExample)
EP (1) EP3265122B1 (enExample)
JP (1) JP6951248B2 (enExample)
KR (1) KR20170122810A (enExample)
CN (1) CN107810013B (enExample)
AU (1) AU2016226157B2 (enExample)
BR (1) BR112017018872A2 (enExample)
CA (1) CA2978311A1 (enExample)
IL (1) IL254133B (enExample)
MX (1) MX386547B (enExample)
RU (1) RU2737216C2 (enExample)
SG (1) SG11201706872SA (enExample)
WO (1) WO2016141209A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HK1252026A1 (zh) * 2015-06-11 2019-05-10 Bionomics Limited 药物组合及其应用
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
WO2018071792A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
WO2018075740A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist
WO2019017497A1 (en) * 2017-07-21 2019-01-24 Eisai R&D Management Co., Ltd. USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
JP7329860B2 (ja) * 2018-06-15 2023-08-21 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ｓ－エクオールを用いた乳癌の治療及び予防方法
AU2019285641A1 (en) 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
JP2022553421A (ja) * 2019-10-28 2022-12-22 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087230A1 (en) * 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
IL139960A0 (en) * 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2578576B9 (en) 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
SG182612A1 (en) 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
ES2644022T3 (es) 2013-03-14 2017-11-27 Bristol-Myers Squibb Company Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
ES2822665T3 (es) * 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
CN105283180A (zh) 2013-06-11 2016-01-27 诺华股份有限公司 Pi3k抑制剂与微管去稳定剂的药物组合
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3114144A1 (en) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR20170039096A (ko) 2014-05-28 2017-04-10 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료에 있어서 에리불린의 용도
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087230A1 (en) * 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer

Also Published As

Publication number Publication date
EP3265122B1 (en) 2022-05-04
IL254133A0 (en) 2017-10-31
US10945990B2 (en) 2021-03-16
CN107810013B (zh) 2021-04-02
CA2978311A1 (en) 2016-09-09
SG11201706872SA (en) 2017-09-28
IL254133B (en) 2021-09-30
US20180071247A1 (en) 2018-03-15
WO2016141209A1 (en) 2016-09-09
MX386547B (es) 2025-03-19
RU2737216C2 (ru) 2020-11-26
BR112017018872A2 (pt) 2018-05-29
RU2017132877A3 (enExample) 2019-08-29
CN107810013A (zh) 2018-03-16
AU2016226157A1 (en) 2017-09-14
JP2018508516A (ja) 2018-03-29
MX2017011206A (es) 2018-05-17
JP6951248B2 (ja) 2021-10-20
KR20170122810A (ko) 2017-11-06
RU2017132877A (ru) 2019-04-05
EP3265122A1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
AU2016226157B2 (en) Combination of a PD-1 antagonist and eribulin for treating cancer
US20220324979A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
US10695426B2 (en) Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
EP3035964B1 (en) Treating cancer with a combination of a pd-1 antagonist and dinaciclib
WO2015119944A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
US20190263927A1 (en) Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
EP3849606A1 (en) Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
HK40010365A (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK40010365B (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired